Trial Profile
A randomized, controlled, multicenter trial for Xiaoyan Granule combined with Apatinib Mesylas in the treatment of advanced non-small cell lung cancer patient
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Dec 2019
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 21 Sep 2018 New trial record